泰恩康(301263.SZ):和胃整腸丸收到藥品註冊受理通知書
格隆匯3月11日丨泰恩康(301263.SZ)公佈,公司全資子公司安徽泰恩康製藥有限公司於近日收到國家藥品監督管理局簽發的和胃整腸丸境內生產藥品註冊上市許可申請《受理通知書》,國家藥監局根據《中華人民共和國行政許可法》第三十二條的規定,對上述藥品的藥品註冊上市許可申請進行了審查,決定予以受理。
“和胃整腸丸”是一種治療腸胃疾病的中成藥,主要作用為温中和胃、理氣止痛,能夠迅速調理腸胃,緩解腹痛腹瀉症狀,安全性和療效顯著,在我國尤其是東南沿海地區享有較高知名度。
流行病學調查研究顯示,功能性胃腸病發病率高,其中以功能性消化不良和腸易激綜合徵最為常見,由於中成藥治療腸胃病具備服用便捷、低副作用等優勢,市場規模呈上升趨勢。根據米內網數據顯示,2023年中國三大終端六大市場胃藥(胃炎、潰瘍)中成藥銷售額超過100億元,2024年上半年其銷售額超過50億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.